Brown S C, Fassati A, Popplewell L, Page A M, Henry M D, Campbell K P, Dickson G
Division of Biochemistry, School of Biological Sciences, Royal Holloway College, University of London, Egham, Surrey TW20 0EX, UK.
J Cell Sci. 1999 Jan;112 ( Pt 2):209-16. doi: 10.1242/jcs.112.2.209.
alpha-dystroglycan is a glycoprotein expressed on the surface of skeletal muscle fibres and other cell types. In muscle, alpha-dystroglycan provides a link between the myofibre cytoskeleton through its indirect binding to dystrophin, and the basal lamina through its binding to laminin-2, a protein of the extracellular matrix. The disruption of this linkage between the myofibre cytoskeleton and the extracellular matrix is a common feature of Duchenne and other muscular dystrophies, though the pathogenic mechanisms leading to muscle wasting remain unknown. By treating primary mouse muscle cultures with a monoclonal antibody which blocks alpha-dystroglycan binding to laminin, we show here the induction of a dystrophic phenotype in vitro. The phenotype is inducible in differentiated cultures only, is characterised by reduced myotube size, myofibril disorganisation, loss of contractile activity, reduced spontaneous clustering of acetylcholine receptors and is reversed by addition of excess exogenous laminin-2. Thus, alpha-dystroglycan may be part of a signalling pathway for the maturation and maintenance of skeletal myofibres. Detailed knowledge of this signalling pathway may provide insights into the molecular pathology of the various inherited muscular dystrophies, and identify valuable pharmacological targets and new therapeutic strategies.
α- dystroglycan是一种在骨骼肌纤维和其他细胞类型表面表达的糖蛋白。在肌肉中,α- dystroglycan通过其与肌营养不良蛋白的间接结合,在肌纤维细胞骨架和通过其与层粘连蛋白-2(细胞外基质的一种蛋白质)的结合之间提供联系。肌纤维细胞骨架和细胞外基质之间这种联系的破坏是杜氏肌营养不良症和其他肌肉营养不良症的一个共同特征,尽管导致肌肉萎缩的致病机制仍然未知。通过用一种阻断α- dystroglycan与层粘连蛋白结合的单克隆抗体处理原代小鼠肌肉培养物,我们在此展示了体外诱导营养不良表型。该表型仅在分化的培养物中可诱导,其特征在于肌管尺寸减小、肌原纤维紊乱、收缩活性丧失、乙酰胆碱受体自发聚集减少,并且通过添加过量的外源性层粘连蛋白-2可逆转。因此,α- dystroglycan可能是骨骼肌纤维成熟和维持信号通路的一部分。对该信号通路的详细了解可能有助于深入了解各种遗传性肌肉营养不良症的分子病理学,并确定有价值的药理学靶点和新的治疗策略。